Skip to main content
    V

    Vericel Corp Ord (VCEL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $54.62
    +2.84 (+5.48%)

    Market Cap: $2.33B

    Last updated: Nov 06, 2026 at 4:35 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    70%(28/40)
    Avg Surprise
    +91.69%
    Streak
    6 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$0.64
    Range$0.57 - $0.83
    5 analysts
    Revenue Consensus
    $122M
    Range$121M - $126M
    8 analysts
    Last 12 of 40 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$0.64$0.57 - $0.83--5--
    Sep 26
    Reported Nov 5
    		$0.27$0.02$0.02 - $0.10+1250.00%Beat5
    1
    0
    30d
    		+170.0%
    Jun 26
    Reported Jul 30
    		$0.04$-0.04$-0.06 - $0.00+200.00%Beat6
    No revisions (30d)
    		+500.0%
    Mar 26
    Reported May 7
    		$-0.12$-0.16$-0.17 - $-0.14+25.00%Beat6
    0
    1
    30d
    		+47.8%
    Dec 25
    Reported Feb 26
    		$0.45$0.45$0.31 - $0.52+0.00%Beat5
    1
    2
    30d
    		+18.4%
    Sep 25
    Reported Nov 6
    		$0.10$-0.01$-0.09 - $0.03+1100.00%Beat6
    0
    3
    30d
    		+600.0%
    Jun 25
    Reported Jul 31
    		$-0.01N/A-+75.00%Beat6
    1
    1
    30d
    		+90.0%
    Mar 25
    Reported May 8
    		$-0.23$-0.15$-0.25 - $-0.06-53.33%Miss6
    1
    1
    30d
    		-187.5%
    Dec 24
    Reported Feb 27
    		$0.38$0.34$0.33 - $0.35+11.76%Beat2
    0
    1
    30d
    		+46.2%
    Sep 24
    Reported Nov 7
    		$-0.02N/A-+60.00%Beat7
    No revisions (30d)
    		+60.0%
    Jun 24
    Reported Aug 1
    		$-0.10$-0.09$-0.15 - $-0.05-11.11%Miss6
    No revisions (30d)
    		+9.1%
    Mar 24
    Reported May 8
    		$-0.08$-0.10$-0.17 - $-0.05+20.00%Beat6
    No revisions (30d)
    		+50.0%
    Dec 23
    Reported Feb 29
    		$0.26$0.17$0.14 - $0.20+52.94%Beat6
    1
    0
    30d
    		+116.7%

    Key Metrics

    Valuation
    P/E Ratio85.34EV/EBITDA65.40x
    Price/FCF48.29xFCF Yield2.07%
    Profitability
    Profit Margin7.91%Operating Margin0.56%
    ROE7.16%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage42.00x
    Current Ratio5.13xQuick Ratio4.82x
    Trading Statistics
    Beta1.06Avg Volume759.25K
    52-Week High$55.6052-Week Low$28.95

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$44.41
    SMA 20$42.69
    SMA 50$41.01
    SMA 200$38.87
    EMA 10$45.83
    EMA 20$43.72
    EMA 50$42.23
    EMA 200$40.07

    MACD

    Line: 2.07Signal: 0.84Hist: 1.23

    ADX

    ADX: 22.3+DI: 44.5-DI: 10.7

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down24.0
    PSAR$40.21

    Bollinger Bands

    Upper Band$50.47
    Lower Band$34.91
    %B Position3644%(Upper)
    Band Width1.27

    RSI (14-Day)

    Overbought
    78.4

    Momentum Oscillators

    Stoch %K87.6
    Stoch %D69.3
    Williams %R-6.1
    ROC (10d)28.4%
    Momentum12.09
    CCI (20d)305.7
    MFI (14d)85.9

    Volatility Measures

    ATR (14d)$2.51(4.6%)
    StdDev (20d)3.89
    Hist Vol73.4%(High)

    Volume Flow

    VWAP$53.34
    OBV20.0M
    AD Line5.2M
    CMF (20d)0.252

    Volume Metrics

    Avg Vol (20d)772.4K
    Vol Ratio2.1x(High)
    VWMA (20d)$45.01

    Pivot Points

    R3$61.85
    R2$58.73
    R1$55.25
    Pivot Point$52.13
    S1$48.65
    S2$45.53
    S3$42.05

    Advanced Oscillators

    TSI29.08
    Ultimate Osc67.6
    KST99.49

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$85.37M$77.46M$68.42M$92.92M$67.50M$63.24M$52.60M$75.38M$57.91M$52.66M$51.28M$65.00M
    Cost of Revenue$22.76M$21.05M$19.16M$19.79M$17.92M$16.63M$16.32M$16.88M$16.25M$16.06M$15.93M$16.49M
    Gross Profit$62.61M$56.40M$49.27M$73.13M$49.59M$46.61M$36.27M$58.50M$41.65M$36.60M$35.35M$48.51M
    Operating Expenses$50.42M$55.97M$57.33M$50.71M$46.13M$48.64M$49.06M$40.02M$44.12M$42.63M$40.82M$35.78M
    R&D$6.88M$7.49M$8.10M$7.25M$6.32M$6.73M$7.26M$4.92M$6.09M$7.36M$6.42M$4.90M
    SG&A$43.54M$48.48M$49.23M$43.46M$39.82M$41.91M$41.80M$35.10M$38.02M$35.27M$34.40M$30.88M
    Operating Income$12.19M$434,000$-8,064,000$22.41M$3.45M$-2,029,000$-12,792,000$18.48M$-2,465,000$-6,031,000$-5,464,000$12.73M
    Interest Income$2.15M$1.95M$1.85M$1.89M$1.81M$1.66M$1.66M$1.56M$1.58M$1.51M$1.76M$1.44M
    Interest Expense$160,000$160,000$160,000$162,000$158,000$157,000$153,000$154,000$154,000$153,000$153,000$156,000
    Income Before Tax$14.16M$2.21M$-6,302,000$24.10M$5.07M$-553,000$-11,246,000$19.95M$-901,000$-4,682,000$-3,862,000$14.09M
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$14.16M$2.21M$-6,302,000$23.24M$5.07M$-553,000$-11,246,000$19.81M$-901,000$-4,682,000$-3,862,000$12.99M
    EBITDA$15.79M$4.03M$-4,699,000$25.58M$6.35M$774,000$-10,129,000$19.96M$-1,123,000$-4,925,000$-4,141,000$13.98M
    EBIT$12.17M$412,000$-7,993,000$22.38M$3.42M$-2,053,000$-12,750,000$18.55M$-2,325,000$-6,039,000$-5,471,000$12.81M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VCEL

    News

    December 2, 2025 is the updated plan adoption date for a proposed $1.53M officer sale at Vericel (VCEL).

    An amended Rule 144 notice for Vericel Corp (VCEL) details a proposed sale of 28,641 common shares, valued at $1,529,937.78...

    Stock Titan•11/6/26•Neutral

    After selling 2,500 shares, Vericel (VCEL) director proposes selling 3,000 more.

    Vericel Corp (VCEL) director Robert L. Zerbe filed a Form 144 notice proposing to sell 3,000 common shares with a market value of $156,682.29. These shares were acquired through a stock option exercise on November 5...

    Stock Titan•11/5/26•Somewhat-Bearish

    Vericel Corp (VCEL) Q3 2026 Earnings Call Transcript

    Vericel Corporation (VCEL) reported a strong third quarter in 2026, with total revenue reaching $85.4 million, a 26% increase year-over-year...

    The Globe and Mail•11/5/26•Bullish

    An officer proposes selling 1,500 Vericel (VCEL) shares acquired through stock options.

    Jonathan D. Siegal, an officer at Vericel Corp (VCEL), has filed a Form 144 notice indicating his intent to sell 1,500 shares of common stock. These shares, valued at $79,350.00...

    Stock Titan•11/5/26•Neutral

    Form 144 Vericel Corp Filed by: SIEGAL JONATHAN

    Jonathan Siegal, an officer at Vericel Corp, has filed a Form 144 indicating a proposed sale of 1,500 shares of common stock. The securities were acquired on November 5, 2026...

    StreetInsider•11/5/26•Neutral

    VCEL Valuation and Fair Value

    P/E
    85.3x
    Forward P/E
    60.6x
    EV/EBITDA
    65.4x
    P/FCF
    48.3x
    PEG
    0.0x
    P/B
    7.3x
    See GNG's fair value

    VCEL Profitability: Margins, ROIC and FCF

    Gross margin
    74.5%
    Operating margin
    0.6%
    Net margin
    7.9%
    ROE
    7.2%
    FCF margin
    17.9%
    FCF yield
    2.1%

    VCEL Competitors

    CompanyTicker
    MBX Biosciences, Inc. Common StockMBX
    UFP Technologies IncUFPT
    89bio IncETNB
    Aurinia Pharmaceuticals IncAUPH
    Clover Health Investments CorpCLOV
    Pharvaris BVPHVS
    Xeris Pharmaceuticals IncXERS
    Palvella Therapeutics, IncPVLA

    Sector: Healthcare

    VCEL Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    0
    Buy
    7
    Hold
    1
    Sell
    0
    Strong Sell
    0

    VCEL Bull Case vs Bear Case

    Bull case

    • VCEL converts 17.9% of revenue into free cash flow.
    • VCEL beat EPS estimates in 75.0% of its last 8 reported quarters.
    • VCEL grew quarterly revenue 22.5% year over year.

    Bear case

    • VCEL trades at 85.3x trailing earnings.

    VCEL Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    326.1%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $0.64

    VCEL Earnings Date

    VCEL reports Feb 24, 2027, after the close. The date is estimated.

    VCEL Earnings Call

    The latest VCEL earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    VCEL ETF Holders

    GNG tracks 14 ETFs that hold VCEL. The largest weights:

    1. abrdn Healthcare Investors (HQH), 0.84% of the fund
    2. State Street SPDR S&P Biotech ETF (XBI), 0.44% of the fund
    3. First Trust Small Cap Growth AlphaDEX Fund (FYC), 0.38% of the fund
    4. iShares Biotechnology ETF (IBB), 0.15% of the fund
    5. iShares Core S&P Small-Cap ETF (IJR), 0.13% of the fund
    Open the ETF Stock Exposure tool for VCEL

    See insider activity

    Frequently Asked Questions About VCEL

    When does VCEL report earnings?

    Vericel Corp Ord (VCEL) is expected to report earnings on Feb 24, 2027.

    Does VCEL pay dividends?

    Vericel Corp Ord (VCEL) does not currently pay a regular dividend.

    What is VCEL's P/E ratio?

    Vericel Corp Ord has a price-to-earnings (P/E) ratio of 85.34.

    What is VCEL's market cap?

    Vericel Corp Ord (VCEL) has a market capitalization of $2.33B with a current stock price of $54.62.

    Related stocks

    Sector: Healthcare

    All stocks starting with V

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In